P/E ratio for Y-mAbs Therapeutics (YMAB)
P/E ratio as of April 2024 (TTM): -17.4
According to Y-mAbs Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -17.4157. At the end of 2022 the company had a P/E ratio of -2.24.
P/E ratio history for Y-mAbs Therapeutics from 2018 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -2.24 | -82.88% |
| 2021 | -13.1 | -21.58% |
| 2020 | -16.7 | 23.22% |
| 2019 | -13.5 | -8.18% |
| 2018 | -14.7 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 ORIC Pharmaceuticals
ORIC | -3.78 | -78.32% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.